Absstract of: EP4840959A1
The invention relates to a nucleic acid molecule for silencing the expression of the gene encoding the transmembrane serine protease type 2 (TMPRSS-2) protein in a cell, an expression cassette for silencing the expression of the gene encoding the TMPRSS-2 protein containing such a nucleic acid molecule, an expression vector for silencing the expression of the gene encoding the TMPRSS-2 protein comprising such a nucleic acid molecule or such an expression cassette, a pharmaceutical composition for silencing the expression of the gene encoding the TMPRSS-2 protein in an organism comprising such a nucleic acid molecule or such an expression cassette or such an expression vector and a pharmaceutically acceptable carrier. The invention also relates to such a nucleic acid molecule for use in therapy, for use in the treatment and/or prevention of a viral disease dependent on a type 2 transmembrane serine protease, preferably in the treatment and/or prevention of severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS), Coronavirus Disease 2019 (COVID-19), influenza, parainfluenza, respiratory syncytial virus (RSV) infection, and Zika fever. The present invention further relates to an in vitro method for silencing the expression of the gene encoding transmembrane serine protease 2 (TMPRSS-2) in a cell, wherein such a nucleic acid molecule or cassette or vector is introduced into the cell and the cell is maintained with the introduced nucleic acid molecule or
Absstract of: WO2021102210A1
Provided herein are methods, systems and devices for detecting a nucleic acid sequences and/or pathogens; including detecting the presence of absence of a target-nucleic acid sequences, including SARS-COV2.
Absstract of: US11149320B1
0001 The present invention is directed to methods for assaying for the presence of SARS-CoV-2 in a sample, including a clinical sample, and to oligonucleotides, reagents, and kits useful in such assays. In particular, the present invention is directed to such assays that are rapid, accurate and specific for the detection of SARS-CoV-2.
Absstract of: AU2025375915A1
Codon-optimized nucleic acids encoding the XBB 1.5 or KP.2 SARS-CoV-2 protein and their use are provided.
Absstract of: US20260355171A1
Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention relates to compounds of Formula (I) and their use for treating or inhibiting the development of a condition in which inhibiting NSP5 activity is associated with effective treatment or inhibition, including a coronavirus infection, for treating or inhibiting the development of a condition associated with a coronavirus infection, for treating or inhibiting the development of neurological symptoms of, and/or neurological complications associated with, a coronavirus infection and for treating or inhibiting the development or progression of long COVID following SARS-CoV-2 infection.
Absstract of: AU2026257536A1
The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self- replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a spike (S) protein or a nucleocapsid (N) protein. ct c t
Absstract of: US20260354407A1
Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.
Absstract of: WO2026236183A1
The technology described herein relates to engineered AAVs and compositions comprising engineered AAVs for use in gene therapies. In some embodiments, described herein are engineered AAVs that can be efficiently delivered to airway and lung cells via intranasal administration.
Absstract of: US20260355302A1
The invention describes a method of generating antibodies to a mixture of SARS-COV-2 peptidogenic proteins or polynucleotides encoding SARS-COV-2 peptidogenic proteins wherein the SARS-COV-2 peptidogenic protein has altered conformational dynamics as compared to a SARS-COV-2 starting protein and wherein the SARS-COV-2 peptidogenic protein has a similar conformation to the SARS-COV-2 starting protein. The SARS-COV-2 peptidogenic proteins can be used to induce an immune response, which can lead to the generation of antibodies and/or can be used to vaccinate a mammal.
Absstract of: US20260355261A1
The invention relates to Corynebacterium strains capable of reducing the expression of cathepsin, and their combinations for use in the prevention of a viral infection, in particular SARS-CoV-2 infection, or for use in the prevention of an infection by an enveloped respiratory virus in a subject, wherein said virus uses cathepsin entry route for entry into the cell of the subject. In particular, said virus is SARS-CoV-2 omicron variant. The invention also relates to lyophilized formulations comprising Corynebacterium strains or combinations thereof, and a cryoprotectant, for use in the prevention of an infection by an enveloped respiratory virus, preferably a SARS-CoV-2 virus in a subject. Preferably, the formulation is administered to the upper respiratory tract of the subject.
Absstract of: US20260356921A1
The invention relates to SARS-CoV-2 binding agents and uses thereof.
Absstract of: US20260355305A1
The invention provides a recombinant virus comprising an influenza viral backbone, wherein the influenza viral backbone comprises PB1, PB2, PA, NP, M, NS, HA, and NA gene segments, wherein at least one of the PB1, PB2, PA, NP, M, NS, HA, and NA gene segments comprises at least one nucleotide sequence that encodes one or more antigens. The invention provides a recombinant virus wherein the antigen is an immunogenic fragment of SARS-COV-2 spike glycoprotein. The invention also provides a pharmaceutical formulation and a method of eliciting an immune response.
Absstract of: US20260355225A1
The invention relates to a formulation comprising at least one compound selected from D-xylose, esters thereof, oligosaccharides comprising D-xylose, and/or β-D-xylosides, for use in stimulating the biosynthesis of glycosaminoglycans, preferably at least one selected from heparan sulfate, dermatan sulfate and chondroitin sulfate, in a human patient, by administering between 1 and 10 doses per day of a composition having a mass of 500 mg to 10 g of said compound. Preferably, said formulation is for use in the prevention or treatment of infections with viruses using syndecans and/or glypicans as cell receptors, such as SARS-CoV-2 or HIV, or in the prevention or treatment of type 2 diabetes or of insulin resistance. The invention also relates to the use of an oral or nasal food supplement composition in healthy subjects to stimulate glycosaminoglycan biosynthesis.
Absstract of: US20260345558A1
A novel benzimidazole-based compound designed to inhibit the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID-19 a method of manufacture, and method of use is disclosed. The compound features a benzimidazole core with a fluorine atom at the 7-position, facilitating pi-stacking interactions with His41 in the Mpro active site. The chiral side chain includes a modified amphetamine backbone with a chiral carbon bearing a methyl group and an isobutyl group, filling the hydrophobic S2 pocket of Mpro. The nitrile warhead forms a covalent bond with the catalytic Cys145 of Mpro, ensuring irreversible inhibition. Additionally, the glutamine-mimicking side chain forms hydrogen bonds with Gln189, Glu166, and Thr190 in the Mpro active site. The compound can be administered in a pharmaceutical composition to treat COVID-19.
Absstract of: US20260345742A1
Compositions and methods are described that are useful for treating and preventing viral infections, such as those by SARS-CoV-2. It is discovered herein that synthetic surfactants such as SMB (SEQ ID NO:7) and B-YL (SEQ ID NO:27) can bind to SARS-CoV-2 Receptor Binding Domain (RBD) and the ACE2 receptor, thereby inhibiting the interaction between the virus and its target cells in the lung, minimizing the infectivity of the virus.
Absstract of: US20260345768A1
0000 The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.
Absstract of: US20260347955A1
0000 Disclosed are methods, compositions and systems for detecting the presence or absence of a pathogen in a sample. The method may include the steps of obtaining a sample from the subject and treating the sample with heat to inactivate any pathogen present in the sample. The method may further include the step of treating the sample to concentrate any pathogen present in the sample. Also, the method may include isolate a pathogen-specific nucleic acid from the heat-inactivated sample and detecting the presence or absence of the isolated pathogen-specific nucleic acid. In certain embodiments, the methods and/or systems may be used to detect SARS-CoV-2. The method may employ real time RT-PCR to provide results in about 3 hours or less.
Absstract of: AU2026257502A1
Abstract The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The method for treating fibrosis comprising administering means for inhibiting Gli1 to a patient in need thereof. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment. Abstract
Absstract of: US20260345710A1
0000 A system and methods for binding to and inhibiting the activity of the SARS-CoV-2 surface spike protein (6VSB) using tulsi extracts from ocimum x africanum is disclosed. One method includes extracting tulsi extracts and administering them to a person through various delivery mechanisms, such as tea, intravenous (IV) fluid, or encapsulated capsules. Another method includes encapsulating fenugreek seeds and neem with tulsi extracts in capsules to enhance the binding and inhibition of SARS-CoV-2 surface spike proteins. Additionally, the invention covers the use of intravenous (IV) fluid containing tulsi extracts, fenugreek seed extracts, and neem extracts for binding to and inhibiting the activity of SARS-CoV-2 surface spike proteins (6VSB).
Absstract of: CA3328600A1
The object of the present invention is to provide an effective antiviral agent against COVID-19. The object can be solved by (1) A polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8, or (2) a polypeptide comprising an amino acid sequence, in which 1 amino acid is substituted in the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, the amino acid sequence of SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of SEQ ID NO: 5, the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8, and having an anti-virus activity against coronavirus, wherein the polypeptide has an O-glycosidic linked sugar chain.
Absstract of: WO2026227737A1
Disclosed in the present invention are a GRFT protein, a GREK1 fusion protein, a nucleic acid encoding same, and use thereof in the preparation of a medicament for preventing or treating: a) paramyxovirus or novel coronavirus infections, and/or b) diseases caused by paramyxovirus or novel coronavirus infections, wherein the GRFT protein comprises an amino acid sequence set forth in SEQ ID NO: 2, and the GREK1 fusion protein comprises an amino acid sequence set forth in SEQ ID NO: 1.
Absstract of: US20260347852A1
0000 The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus
Absstract of: EP4834433A2
0001 A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
Absstract of: WO2025140539A1
Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.
Nº publicación: MD1994Y 31/10/2026
Applicant:
IP UNIV DE STAT DE MEDICINA SI FARMACIE NICOLAE TESTEMITANU DIN REPUBLICA MOLDOVA [MD]
\u041F\u0423 \u0413\u041E\u0421\u0423\u0414\u0410\u0420\u0421\u0422\u0412\u0415\u041D\u041D\u042B\u0419 \u0423\u041D\u0418\u0412\u0415\u0420\u0421\u0418\u0422\u0415\u0422 \u041C\u0415\u0414\u0418\u0426\u0418\u041D\u042B \u0418 \u0424\u0410\u0420\u041C\u0410\u0426\u0418\u0418 \"NICOLAE TESTEMITANU\" \u0420\u0415\u0421\u041F\u0423\u0411\u041B\u0418\u041A\u0418 \u041C\u041E\u041B\u0414\u041E\u0412\u0410
Absstract of: MD1994Y
The invention relates to medicine, in particular to phthisiology and pulmonology, clinical immunology, allergology and pathophysiology, and can be used for diagnosing pulmonary tuberculosis in combination with certain viral infections in patients with secondary immunodeficiency.Summary of the invention consists in that an immunological study of peripheral blood is performed with the determination of the following indicators: the number of lymphocytes, the functional activity of lymphocytes in the test using the transformation reaction of lymphocyte blasts with phytohemagglutinin, the glucose consumption from the supernatant obtained from the cultivation of lymphocytes in the test using the transformation reaction of lymphocyte blasts with phytohemagglutinin, the activity of lactate dehydrogenase and lymphocyte aldolase, and if the results of the determined indicators show a deficit within <1/3 compared to the indicators in practically healthy sunjects, monoinfection with tuberculosis is diagnosed; if the results of the indicators show a deficit of 1/3…2/3 compared to the indicators in practically healthy subjects, the combination of tuberculosis with infection with the human immunodeficiency virus is diagnosed; and if the results of the indicators show a deficit of >2/3 compared to the indicators in practically healthy subjects, the combination of tuberculosis with human immunodeficiency virus infection and COVID-19 is diagnosed.